Recent Updates
Recently added Catalysts

Treprostinil Palmitil

Phase 3

Progressive Pulmonary Fibrosis | Small Molecules | Respiratory |Insmed Incorporated|Trials Updated: Nov 10, 2026

Treprostinil Palmitil development status

Highest phase Phase 3
Registered trials 5 across 1 sponsor since Mar 2021

Treprostinil Palmitil target and mechanism

Molecular targetPTGIR
Target classAgonist
ModalitySmall Molecules

Also known as Treprostinil Palmitil Inhalation Powder, INS1009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials9
Total Enrollment2,125

FDA Designations

No designations recorded

Treprostinil Palmitil clinical trials

Treprostinil Palmitil · 9 trials · 5 indications

Phase 3 4Phase 2/3 2Phase 2 2Phase 1 1
NCT07805785A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Progressive Pulmonary Fibrosis
RECRUITING800 Analytics
NCT07481981A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension
RECRUITING344 Analytics
NCT07234032An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pulmonary Hypertension
RECRUITING344 Analytics
NCT07179380Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pulmonary Hypertension
RECRUITING344 Analytics
PHASE3RECRUITING
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
Progressive Pulmonary FibrosisUnlock trial analytics
PHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial HypertensionUnlock trial analytics
PHASE3RECRUITING
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary HypertensionUnlock trial analytics
PHASE3RECRUITING
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary HypertensionUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Absolute Forced Vital Capacity (FVC) at Week 52
Baseline, Week 52
Change in 6-Minute Walk Distance (6MWD) Measured at 1 to 3 Hours Post-Dose From Baseline at Week 24
Baseline, Week 24
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)
Up to 108 weeks
Change in 6 Minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 24
Baseline, Week 24
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
Up to approximately 25 months
Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity
From screening up to last follow up visit (Up to approximately 26 months)
Number of Participants Who Experience Any Number of Treatment Emergent Adverse Events (TEAEs)
Up to Day 140
Number of Participants Who Experience Any Number of Serious Adverse Events (SAEs)
Up to Day 140
Change from Baseline in Saturation of Peripheral Capillary Oxygenation (SpO2) Levels
Pre-, during, and post- 6-minute walk test (6MWT) at Baseline, Week 5, Week 10, and Week 16
Change from Baseline in Pulmonary Vascular Resistance at Week 16
Baseline to Week 16
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Treprostinil Palmitil (TP) and Treprostinil (TRE)
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Maximum Observed Plasma Concentration (Cmax) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Apparent Total Clearance (CL/F) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Apparent Terminal Elimination Half-Life (t1/2) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Time to Maximum Observed Concentration (Tmax) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Apparent Volume of Distribution (Vz/F) of TP and TRE
Pre-dose and at multiple timepoints post-dose up to Day 3

Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.

Secondary Endpoints

Time to First Clinical Worsening Event
Up to 104 weeks
Time to First Acute Exacerbation of Interstitial Lung Disease (ILD)
Up to 104 weeks
Absolute Change From Baseline in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) % Predicted Corrected for Hemoglobin at Week 52
Baseline, Week 52
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treprostinil Palmitil Inhalation Powder (TPIP)EXPERIMENTALParticipants will receive TPIP, once daily (QD), at a starting dose of 80 micrograms (μg) to the maximum tolerated dose (up to 1280 μg) for up to 104 weeks.
PlaceboPLACEBO_COMPARATORParticipants will receive a TPIP-matching placebo, QD for up to 104 weeks.
Treprostinil Palmitil Inhalation PowderEXPERIMENTALParticipants will receive TPIP, once daily (QD), at a starting dose of 80 micrograms (μg) up to maximum tolerated dose (up to 1280 μg) for 24 weeks.
Treprostinil PalmitilEXPERIMENTALParticipants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
Group 1: Treprostinil Palmitil Inhalation PowderEXPERIMENTALHealthy participants with normal hepatic function will receive a single dose of TPIP on Day 1.
Group 2: Treprostinil Palmitil Inhalation PowderEXPERIMENTALParticipants with mild hepatic impairment (classified based on the numerical Child-Pugh total score of 5 to 6) will receive a single dose of TPIP on Day 1.
Group 3: Treprostinil Palmitil Inhalation PowderEXPERIMENTALParticipants with moderate hepatic impairment (classified based on the numerical Child-Pugh total score of 7 to 9) will receive a single dose of TPIP on Day 1.
Group 4: Treprostinil Palmitil Inhalation PowderEXPERIMENTALParticipants with severe hepatic impairment (classified based on the numerical Child-Pugh total score of 10 to 15) will receive a single dose of TPIP on Day 1.

Interventions

NameTypeDescription
Treprostinil Palmitil Inhalation PowderDRUGOral inhalation using a capsule-based dry powder inhaler device.
PlaceboDRUGOral inhalation using a capsule-based dry powder inhaler device.
Treprostinil PalmitilDRUGAdministered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Radiologic evidence of pulmonary fibrosis of \>10% extent on high-resolution computed tomography (HRCT) in the previous 12 months. * Diagnosis of interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis \[IPF\]) that fulfills at least 1 of the following criter...

Countries:United StatesArgentinaAustraliaIsraelJapanNew ZealandSouth KoreaTaiwanCzechiaFranceGeorgiaGermanySpainAustriaBelgiumBrazilColombiaDenmarkGreeceItalyMalaysiaMexicoPhilippinesPolandPortugalRomaniaSerbiaSwitzerlandTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 10, 2026NCT07234032lastUpdatePostDate: changed
LOWNov 9, 2026NCT07643155lastUpdatePostDate: changed
LOWNov 9, 2026NCT07643155lastUpdatePostDate: changed
LOWNov 2, 2026NCT07805785Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 2, 2026NCT07805785Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 27, 2026NCT07643155lastUpdatePostDate: changed
LOWOct 27, 2026NCT07234032lastUpdatePostDate: changed
LOWOct 27, 2026NCT07643155lastUpdatePostDate: changed
LOWOct 27, 2026NCT07234032lastUpdatePostDate: changed
LOWOct 26, 2026NCT07179380lastUpdatePostDate: changed
LOWOct 26, 2026NCT07179380lastUpdatePostDate: changed
LOWOct 20, 2026NCT05649748lastUpdatePostDate: changed
LOWOct 20, 2026NCT05649748lastUpdatePostDate: changed
LOWOct 13, 2026NCT07481981lastUpdatePostDate: changed
LOWOct 13, 2026NCT07179380lastUpdatePostDate: changed
LOWOct 13, 2026NCT07481981lastUpdatePostDate: changed
LOWOct 13, 2026NCT07179380lastUpdatePostDate: changed
LOWSep 29, 2026NCT07179380lastUpdatePostDate: changed
LOWSep 29, 2026NCT07179380lastUpdatePostDate: changed
LOWSep 16, 2026NCT07481981lastUpdatePostDate: changed

Frequently asked questions about Treprostinil Palmitil

What is Treprostinil Palmitil?

Treprostinil Palmitil is an investigational small molecule developed by Insmed Incorporated as an inhalation powder. It is being studied in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, progressive pulmonary fibrosis, and hepatic impairment. It is also known as Treprostinil Palmitil Inhalation Powder, or TPIP.

What does Treprostinil Palmitil target?

Treprostinil Palmitil targets PTGIR, the prostacyclin receptor, and acts as an agonist at that receptor. Agonism of PTGIR is the mechanism attributed to the compound in its development as an inhaled small molecule for pulmonary vascular and fibrotic lung conditions.

Who makes Treprostinil Palmitil?

Treprostinil Palmitil is developed by Insmed Incorporated, which trades under the ticker INSM. Insmed is the sponsor listed for the clinical trials of Treprostinil Palmitil Inhalation Powder, including the Phase 3 studies in pulmonary arterial hypertension and progressive pulmonary fibrosis.

Is Treprostinil Palmitil FDA approved?

Treprostinil Palmitil is investigational and has not been approved for any indication. It remains in clinical development, with Phase 3 trials recruiting in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and progressive pulmonary fibrosis, plus a Phase 1 pharmacokinetic study in hepatic impairment.

What clinical trials is Treprostinil Palmitil in?

Treprostinil Palmitil is in four registered trials. NCT07481981 is a Phase 3 study in pulmonary arterial hypertension, NCT07805785 a Phase 3 study in progressive pulmonary fibrosis, and NCT07234032 a Phase 3 open-label extension in pulmonary hypertension with interstitial lung disease. NCT07643155 is a Phase 1 pharmacokinetic and safety study in hepatic impairment.

Is Treprostinil Palmitil the same as Treprostinil Palmitil Inhalation Powder?

Yes. Treprostinil Palmitil Inhalation Powder, abbreviated TPIP, is the same investigational asset as Treprostinil Palmitil. The longer name describes the inhaled powder formulation used across the Insmed clinical program, and both names refer to the same PTGIR agonist compound.